Eli Lilly has surpassed analysts’ highest hopes for the efficacy of retatrutide, linking the triple agonist to 28.7% weight loss and a 75.8% reduction in pain scores in patients with obesity and knee ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback